Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Current Leases (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Current Leases for 2 consecutive years, with $2.7 million as the latest value for Q3 2025.

  • Quarterly Current Leases rose 659.61% to $2.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Sep 2025, up 659.61% year-over-year, with the annual reading at $208000.0 for FY2024, N/A changed from the prior year.
  • Current Leases hit $2.7 million in Q3 2025 for Prelude Therapeutics, up from $2.7 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.7 million in Q3 2025 to a low of $53000.0 in Q1 2025.